Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer

Urol Nurs. 2013 Sep-Oct;33(5):236-44, 248.

Abstract

This multicenter, randomized, crossover, open-label study (ClinicalTrials.gov identifier: NCT01161563) assessed patients'and clinicians'perceptions of injection site tolerability and adverse events following the intramuscular injection of triptorelin pamoate or subcutaneous injection of leuprolide acetate in 107 male, patients with advanced prostate cancer.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects
  • Cross-Over Studies
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Leuprolide / administration & dosage*
  • Leuprolide / adverse effects
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / nursing
  • Triptorelin Pamoate / administration & dosage*
  • Triptorelin Pamoate / adverse effects

Substances

  • Antineoplastic Agents, Hormonal
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Leuprolide

Associated data

  • ClinicalTrials.gov/NCT01161563